(CercleFinance.com) – Moderna announces that Swissmedic has granted temporary authorization for the use of its bivalent booster vaccine targeting Omicron, Spikevax Bivalent, for active immunization to prevent Covid-2019 in 18-year-olds and more in Switzerland.
The decision by Swissmedic, the Swiss health authority, is based on clinical data from a phase 2/3 trial, in which mRNA-1273.214 met all primary endpoints, and was generally well tolerated.
Moderna is working with local authorities to make Spikevax Bivalent Original/Omicron available to the Swiss, with the aim of supplying the product in early September. Switzerland becomes one of the first countries in the world to approve the use of the product.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
